CTIS2023-508820-37-00
Active, not recruiting
Phase 1
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age - mRNA1647-P301
Overview
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Moderna Inc.
- Enrollment
- 7,484
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Ages
- 0 to 64 (—)
- Sex
- All
Inclusion Criteria
- •1\. Is a female and 16 to 40 years of age, at the time of consent. 2\. According to the assessment of the Investigator, is capable of complying with study procedures. 3\. For female participants aged \= 20 years, has or anticipates having direct exposure within 7 months after planned first dose (in the home, socially, or occupationally) to at least 1 child \= 5 years of age. Direct exposure is defined as either a) participant is the parent, or b) participant has close contact (feeding, diaper changes, childcare/supervision) for at least 8 hours per week. 4\. For the CMV\-seronegative Cohorts: at the Screening visit, is CMV IgGnegative and CMV immunoglobulin M (IgM)\-negative; For CMVseropositive Cohorts: at the Screening visit, is CMV IgG\-positive and CMV IgMnegative, or CMV IgG\-positive and CMV IgM\-positive. Participants with an isolated positive result for CMV IgM (ie, CMV IgG\-negative and CMV IgM\-positive) will not be eligible for enrollment but may be rescreened after at least 6 weeks from the initial CMV screening. A participant with a CMV IgG\-positive result and an IgM\-indeterminate result at Screening will not require the IgM sampling to be repeated in order to consider the participant CMV\-seropositive. 5\. Participants (and parent/LAR, if applicable) provides written informed consent/assent. Participants under the age of majority (ie, under legal age) at the time of enrollment must provide written informed consent at the next study visit once turning the age of majority. 6\. Investigator assessment confirms that the participant (including in the case of an emancipated minor), or parent(s)/LAR(s), as applicable, understands and is willing and physically able to comply with protocol mandated follow\-up including all study visits and procedures anticipated during the 30\-month study period. 7\. This criterion has been removed in Protocol Amendment 2: Has a body mass index of 15\-35 kg/m2, inclusive. 8\. Female participants of childbearing potential: Urine pregnancy test is negative at Screening and negative on the day of the first injection (Day 1\). Note: urine pregnancy test at Screening or Day 1 is not required for female participants of nonchildbearing potential. See Section 11\.8 for definition of nonchildbearing potential. 9\. Female participants of childbearing potential: If the participant is sexually active with men, all of the following criteria must be met: • Has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (Day 1\). • Agrees to continue adequate contraception through 3 months following the third study injection (Month 9/Day 257\). Adequate contraception is defined as consistent and correct use of an approved contraceptive method in accordance with the product label, or sterilization of a monogamous male partner prior to study enrollment.
Exclusion Criteria
- •1\-9: 1\. This criterion has been removed in Protocol Amendment 2: Female participants: Is of nonchildbearing potential. Nonchildbearing potential is defined as one of the following: • Surgically sterile (reports history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy). • Postmenopausal state (reports history of amenorrhea for \= 12 consecutive months prior to Screening without an alternative medical cause). 2\. History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures. Clinically unstable is defined as a diagnosis or condition requiring significant changes in management or medication within the 2 months prior to Screening, and includes ongoing workup of an undiagnosed illness that could lead to a new diagnosis or condition. This includes but is not limited to: • Reported history of congenital or acquired immunodeficiency, immunosuppressive condition, or immune\-mediated disease. • Dermatologic conditions that could affect local solicited AR assessments (eg, tattoos; psoriasis patches affecting skin over the deltoid areas). • Reported history of anaphylaxis or severe hypersensitivity reaction after receipt of the mRNA\-1647 vaccine or any components of the mRNA\- 1647 vaccine. • Reported history of bleeding disorder that is considered a contraindication to intramusculary (IM) injection or phlebotomy. • Any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results. 3\. Received or plans to receive any non study vaccine \< 28 days prior to and after any study injection; in addition, the following criteria for COVID\-19 and influenza vaccines apply: \- Any COVID\-19 primary vaccination series must have been completed a minimum of 28 days prior to receiving any dose of the study injection. \- COVID\-19 vaccines (including any booster dose, regardless of manufacturer) must be administered at least 28 days prior to or after any study injection. \- Influenza vaccines may be administered \> 14 days prior to or after any study injection. 4\. Received systemic immunosuppressants or immune\-modifying drugs for \> 14 days in total within 6 months prior to the day of first injection (Day 1\) (for corticosteroids, \= 5 mg/day of prednisone equivalent) or plans to do so during the course of the study. Inhaled, nasal, and topical steroids are allowed. Stable immunomodulator regimens used for managing environmental allergies are allowed. 5\. Receipt of an antiviral with activity against CMV (ganciclovir, valganciclovir, foscarnet, cidofovir, letermovir, acyclovir, valacyclovir) \< 2 weeks prior to the day of first injection or plans to do so during the course of the study. 6\. Previous receipt of an investigational CMV vaccine. 7\. Receipt of systemic immunoglobulins or blood products \< 3 months prior to the day of first injection. 8\. Has donated \= 450 mL of blood products \< 28 days prior to Screening. 9\. Participated in an interventional clinical study \< 28 days prior to the day of first injection (Day 1\) or plans to do so while enrolled in this study., 10\-10: 10\. Is a member of study team or is an immediate family member or household member of study personnel.
Investigators
Similar Trials
Active, not recruiting
Phase 1
This clinical study is for patients with advanced non-small cell lung cancer (NSCLC). One half of subjects will be given the experimental drug ARQ 19 tablets together with the approved medicine Tarceva (Erlotinib), while the other half will be given placebo (dummy) tablets together with Tarceva. The study is double blind in its design meaning neither the patient nor the clinical staff participating in the study will known whether they are give the experimental drug ARQ197 or placebo.EUCTR2010-022365-10-ATDaiichi Sankyo Development Limited988
Recruiting
Phase 3
A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients with Acquired Hypothalamic ObesityAcquired hypothalamic obesity (HO)JPRN-jRCT2041230156Flaherty Jim12
Recruiting
Phase 1
Phase 3 Trial of Setmelanotide in Acquired Hypothalamic ObesityAcquired Hypothalamic ObesityTherapeutic area: Phenomena and Processes [G] - Metabolism [G03]Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]CTIS2022-503116-16-00Rhythm Pharmaceuticals Inc.120
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataJPRN-jRCT2051220189Masaki Takeshi595
Active, not recruiting
Phase 1
A clinical trial where neither the doctor, patient or sponsor know whether a placebo or active medicine is being given to the patient with compensated cirrhosis due to nonalcoholic steatohepatitis to see if the medicine is effective and safe in the treatment of that diseaseEUCTR2017-000474-11-ESIntercept Pharmaceuticals, Inc.540